Airsupra Dosing Information
I cannot provide specific dosing recommendations for Airsupra because none of the provided evidence contains information about this medication. The evidence provided discusses traditional albuterol formulations, nebulized bronchodilators, and a combination albuterol/budesonide product, but does not include FDA labeling or guidelines specific to "Airsupra."
What the Evidence Does Show
Albuterol/Budesonide Combination Products
The most relevant evidence discusses a pressurized metered-dose inhaler containing albuterol and budesonide approved by the FDA for as-needed treatment in adults ≥18 years with asthma 1.
Key characteristics of this combination product:
- Approved for as-needed (reliever) use to treat or prevent bronchoconstriction and reduce exacerbation risk 1
- Can be used with or without maintenance therapy, but is NOT indicated as maintenance therapy itself 1
- Not approved for single maintenance and reliever therapy (SMART) 1
- Represents a paradigm shift by intervening during loss of asthma control with both bronchodilator and anti-inflammatory effects 1
- Shown to decrease asthma exacerbations and oral corticosteroid burden in patients with moderate-to-severe asthma 1
Standard Albuterol Dosing for Context
If Airsupra contains albuterol as a component, standard albuterol dosing guidelines include:
For routine asthma/COPD management:
- 2 puffs (90 mcg/puff) every 4-6 hours as needed, not exceeding 8 puffs per day 2
- Should be used as rescue medication only, not for long-term daily treatment 2
For acute exacerbations:
- 4-8 puffs via MDI with spacer every 20 minutes for 3 doses, then every 1-4 hours as needed 3
- Nebulized: 2.5-5 mg every 20 minutes for 3 doses, then 2.5-10 mg every 1-4 hours 3
Critical Gap
Without FDA labeling or specific prescribing information for Airsupra, I cannot provide accurate dosing recommendations. Dosing for combination products differs from individual components and must follow the specific approved labeling for that product.